D
Alnylam Pharmaceuticals, Inc.
ALNY
$248.13
-$1.10-0.44%
D
Sell
2/3/2025Upgraded
Alnylam Pharmaceuticals, Inc. (ALNY) was upgraded to D- from E+ on 2/3/2025 due to an increase in the solvency index and volatility index.
Alnylam Pharmaceuticals, Inc. (ALNY) was upgraded to D- from E+ on 2/3/2025 due to an increase in the solvency index and volatility index.
E
Sell
11/4/2024Downgrade
Alnylam Pharmaceuticals, Inc. (ALNY) was downgraded to E+ from D- on 11/4/2024 due to a significant decline in the growth index, solvency index and valuation index. Earnings per share declined from -$0.1333 to -$0.87, EBIT declined 258.2% from $48.61M to -$76.91M, and debt to equity increased from -804.98 to 76.97.
Alnylam Pharmaceuticals, Inc. (ALNY) was downgraded to E+ from D- on 11/4/2024 due to a significant decline in the growth index, solvency index and valuation index. Earnings per share declined from -$0.1333 to -$0.87, EBIT declined 258.2% from $48.61M to -$76.91M, and debt to equity increased from -804.98 to 76.97.
D
Sell
6/25/2024Upgraded
Alnylam Pharmaceuticals, Inc. (ALNY) was upgraded to D- from E+ on 6/25/2024 due to a significant increase in the growth index, volatility index and solvency index. EBIT increased 62.69% from -$116.4M to -$43.44M, earnings per share increased from -$1.0976 to -$0.5227, and total revenue increased 12.42% from $439.72M to $494.33M.
Alnylam Pharmaceuticals, Inc. (ALNY) was upgraded to D- from E+ on 6/25/2024 due to a significant increase in the growth index, volatility index and solvency index. EBIT increased 62.69% from -$116.4M to -$43.44M, earnings per share increased from -$1.0976 to -$0.5227, and total revenue increased 12.42% from $439.72M to $494.33M.
E
Sell
4/11/2024Downgrade
Alnylam Pharmaceuticals, Inc. (ALNY) was downgraded to E+ from D- on 4/11/2024 due to a large decline in the total return index, growth index and volatility index. Earnings per share declined from $1.1518 to -$1.0976, EBIT declined 154.43% from $213.87M to -$116.4M, and operating cash flow declined 108.29% from $359.41M to -$29.8M.
Alnylam Pharmaceuticals, Inc. (ALNY) was downgraded to E+ from D- on 4/11/2024 due to a large decline in the total return index, growth index and volatility index. Earnings per share declined from $1.1518 to -$1.0976, EBIT declined 154.43% from $213.87M to -$116.4M, and operating cash flow declined 108.29% from $359.41M to -$29.8M.
D
Sell
3/14/2023Downgrade
Alnylam Pharmaceuticals, Inc. (ALNY) was downgraded to D- from D+ on 3/14/2023 due to a major decline in the total return index and solvency index. Debt to equity increased from -15.64 to -6.69, and the quick ratio declined from 3.17 to 3.16.
Alnylam Pharmaceuticals, Inc. (ALNY) was downgraded to D- from D+ on 3/14/2023 due to a major decline in the total return index and solvency index. Debt to equity increased from -15.64 to -6.69, and the quick ratio declined from 3.17 to 3.16.
D
Sell
2/9/2023Upgraded
Alnylam Pharmaceuticals, Inc. (ALNY) was upgraded to D+ from D- on 02/09/2023.
Alnylam Pharmaceuticals, Inc. (ALNY) was upgraded to D+ from D- on 02/09/2023.
D
Sell
2/8/2023Downgrade
Alnylam Pharmaceuticals, Inc. (ALNY) was downgraded to D- from D+ on 2/8/2023 due to a noticeable decline in the total return index and valuation index.
Alnylam Pharmaceuticals, Inc. (ALNY) was downgraded to D- from D+ on 2/8/2023 due to a noticeable decline in the total return index and valuation index.
D
Sell
10/28/2022Upgraded
Alnylam Pharmaceuticals, Inc. (ALNY) was upgraded to D+ from D on 10/28/2022 due to a significant increase in the total return index, valuation index and solvency index. Debt to equity declined from 4.08 to -15.64.
Alnylam Pharmaceuticals, Inc. (ALNY) was upgraded to D+ from D on 10/28/2022 due to a significant increase in the total return index, valuation index and solvency index. Debt to equity declined from 4.08 to -15.64.
D
Sell
4/29/2022Upgraded
Alnylam Pharmaceuticals, Inc. (ALNY) was upgraded to D from D- on 4/29/2022 due to an increase in the growth index and total return index. EBIT increased 24.58% from -$194.56M to -$146.73M, and earnings per share increased from -$2.1579 to -$2.
Alnylam Pharmaceuticals, Inc. (ALNY) was upgraded to D from D- on 4/29/2022 due to an increase in the growth index and total return index. EBIT increased 24.58% from -$194.56M to -$146.73M, and earnings per share increased from -$2.1579 to -$2.
D
Sell
4/20/2022Downgrade
Alnylam Pharmaceuticals, Inc. (ALNY) was downgraded to D- from D on 4/20/2022 due to a decline in the solvency index, volatility index and growth index. Debt to equity increased from 0.63 to 1.22, earnings per share declined from -$1.7166 to -$2.1579, and operating cash flow declined 12.02% from -$134.04M to -$150.14M.
Alnylam Pharmaceuticals, Inc. (ALNY) was downgraded to D- from D on 4/20/2022 due to a decline in the solvency index, volatility index and growth index. Debt to equity increased from 0.63 to 1.22, earnings per share declined from -$1.7166 to -$2.1579, and operating cash flow declined 12.02% from -$134.04M to -$150.14M.
D
Sell
2/3/2022Downgrade
Alnylam Pharmaceuticals, Inc. (ALNY) was downgraded to D from D+ on 2/3/2022 due to a major decline in the total return index and volatility index.
Alnylam Pharmaceuticals, Inc. (ALNY) was downgraded to D from D+ on 2/3/2022 due to a major decline in the total return index and volatility index.
D
Sell
11/9/2021Upgraded
Alnylam Pharmaceuticals, Inc. (ALNY) was upgraded to D+ from D- on 11/09/2021.
Alnylam Pharmaceuticals, Inc. (ALNY) was upgraded to D+ from D- on 11/09/2021.
D
Sell
11/8/2021Downgrade
Alnylam Pharmaceuticals, Inc. (ALNY) was downgraded to D- from D+ on 11/8/2021 due to a decline in the valuation index.
Alnylam Pharmaceuticals, Inc. (ALNY) was downgraded to D- from D+ on 11/8/2021 due to a decline in the valuation index.
D
Sell
9/7/2021Upgraded
Alnylam Pharmaceuticals, Inc. (ALNY) was upgraded to D+ from D on 9/7/2021 due to an increase in the total return index and volatility index.
Alnylam Pharmaceuticals, Inc. (ALNY) was upgraded to D+ from D on 9/7/2021 due to an increase in the total return index and volatility index.
D
Sell
7/26/2021Downgrade
Alnylam Pharmaceuticals, Inc. (ALNY) was downgraded to D from D+ on 7/26/2021 due to a decline in the volatility index and valuation index.
Alnylam Pharmaceuticals, Inc. (ALNY) was downgraded to D from D+ on 7/26/2021 due to a decline in the volatility index and valuation index.
D
Sell
6/28/2021Upgraded
Alnylam Pharmaceuticals, Inc. (ALNY) was upgraded to D+ from D on 6/28/2021 due to a substantial increase in the growth index and volatility index. Earnings per share increased from -$2.0945 to -$1.7107, total revenue increased 8.56% from $163.56M to $177.57M, and EBIT increased 4.1% from -$194.22M to -$186.25M.
Alnylam Pharmaceuticals, Inc. (ALNY) was upgraded to D+ from D on 6/28/2021 due to a substantial increase in the growth index and volatility index. Earnings per share increased from -$2.0945 to -$1.7107, total revenue increased 8.56% from $163.56M to $177.57M, and EBIT increased 4.1% from -$194.22M to -$186.25M.
D
Sell
5/1/2020Upgraded
Alnylam Pharmaceuticals, Inc. (ALNY) was upgraded to D from D- on 5/1/2020 due to an increase in the total return index and volatility index.
Alnylam Pharmaceuticals, Inc. (ALNY) was upgraded to D from D- on 5/1/2020 due to an increase in the total return index and volatility index.
D
Sell
2/18/2020Downgrade
Alnylam Pharmaceuticals, Inc. (ALNY) was downgraded to D- from D on 2/18/2020 due to a decline in the solvency index, growth index and efficiency index. EBIT declined 37.81% from -$216.3M to -$298.07M, net income declined 32.44% from -$208.54M to -$276.19M, and earnings per share declined from -$1.9184 to -$2.4715.
Alnylam Pharmaceuticals, Inc. (ALNY) was downgraded to D- from D on 2/18/2020 due to a decline in the solvency index, growth index and efficiency index. EBIT declined 37.81% from -$216.3M to -$298.07M, net income declined 32.44% from -$208.54M to -$276.19M, and earnings per share declined from -$1.9184 to -$2.4715.
D
Sell
5/7/2019Upgraded
Alnylam Pharmaceuticals, Inc. (ALNY) was upgraded to D from D- on 5/7/2019 due to an increase in the total return index, efficiency index and solvency index. Total capital increased 40.86% from $1.33B to $1.88B, the quick ratio increased from 6.21 to 8.57, and net income increased 13.96% from -$211.44M to -$181.92M.
Alnylam Pharmaceuticals, Inc. (ALNY) was upgraded to D from D- on 5/7/2019 due to an increase in the total return index, efficiency index and solvency index. Total capital increased 40.86% from $1.33B to $1.88B, the quick ratio increased from 6.21 to 8.57, and net income increased 13.96% from -$211.44M to -$181.92M.
D
Sell
2/15/2019Downgrade
Alnylam Pharmaceuticals, Inc. (ALNY) was downgraded to D- from D on 2/15/2019 due to a large decline in the total return index, efficiency index and solvency index. The quick ratio declined from 10.45 to 6.21, and total capital declined 11.68% from $1.51B to $1.33B.
Alnylam Pharmaceuticals, Inc. (ALNY) was downgraded to D- from D on 2/15/2019 due to a large decline in the total return index, efficiency index and solvency index. The quick ratio declined from 10.45 to 6.21, and total capital declined 11.68% from $1.51B to $1.33B.
D
Sell
4/4/2018Downgrade
Alnylam Pharmaceuticals, Inc. (ALNY) was downgraded to D from D+ on 4/4/2018 due to a noticeable decline in the total return index and volatility index.
Alnylam Pharmaceuticals, Inc. (ALNY) was downgraded to D from D+ on 4/4/2018 due to a noticeable decline in the total return index and volatility index.
D
Sell
3/13/2018Upgraded
Alnylam Pharmaceuticals, Inc. (ALNY) was upgraded to D+ from D on 3/13/2018 due to an increase in the solvency index, growth index and efficiency index. Total revenue increased 121.83% from $17.1M to $37.92M, debt to equity declined from 0.14 to 0.02, and total capital increased 48.61% from $1.21B to $1.8B.
Alnylam Pharmaceuticals, Inc. (ALNY) was upgraded to D+ from D on 3/13/2018 due to an increase in the solvency index, growth index and efficiency index. Total revenue increased 121.83% from $17.1M to $37.92M, debt to equity declined from 0.14 to 0.02, and total capital increased 48.61% from $1.21B to $1.8B.
D
Sell
11/9/2017Downgrade
Alnylam Pharmaceuticals, Inc. (ALNY) was downgraded to D from D+ on 11/9/2017 due to a decline in the solvency index, efficiency index and valuation index. Debt to equity increased from 0.13 to 0.14, total capital declined 5.04% from $1.27B to $1.21B, and net income declined 3.81% from -$118.42M to -$122.94M.
Alnylam Pharmaceuticals, Inc. (ALNY) was downgraded to D from D+ on 11/9/2017 due to a decline in the solvency index, efficiency index and valuation index. Debt to equity increased from 0.13 to 0.14, total capital declined 5.04% from $1.27B to $1.21B, and net income declined 3.81% from -$118.42M to -$122.94M.
D
Sell
10/11/2017Upgraded
Alnylam Pharmaceuticals, Inc. (ALNY) was upgraded to D+ from D on 10/11/2017 due to a significant increase in the total return index, solvency index and volatility index. The quick ratio increased from 6.05 to 8.63, and debt to equity declined from 0.18 to 0.13.
Alnylam Pharmaceuticals, Inc. (ALNY) was upgraded to D+ from D on 10/11/2017 due to a significant increase in the total return index, solvency index and volatility index. The quick ratio increased from 6.05 to 8.63, and debt to equity declined from 0.18 to 0.13.
D
Sell
5/10/2017Upgraded
Alnylam Pharmaceuticals, Inc. (ALNY) was upgraded to D from D- on 5/10/2017 due to a large increase in the growth index and volatility index. Total revenue increased 8.63% from $17.45M to $18.96M, EBIT increased 7.73% from -$115.43M to -$106.51M, and earnings per share increased from -$1.3156 to -$1.2472.
Alnylam Pharmaceuticals, Inc. (ALNY) was upgraded to D from D- on 5/10/2017 due to a large increase in the growth index and volatility index. Total revenue increased 8.63% from $17.45M to $18.96M, EBIT increased 7.73% from -$115.43M to -$106.51M, and earnings per share increased from -$1.3156 to -$1.2472.
D
Sell
11/14/2016Downgrade
Alnylam Pharmaceuticals, Inc. (ALNY) was downgraded to D- from D on 11/14/2016 due to a noticeable decline in the total return index, volatility index and solvency index. The quick ratio declined from 12.27 to 8.91, and debt to equity increased from 0.14 to 0.15.
Alnylam Pharmaceuticals, Inc. (ALNY) was downgraded to D- from D on 11/14/2016 due to a noticeable decline in the total return index, volatility index and solvency index. The quick ratio declined from 12.27 to 8.91, and debt to equity increased from 0.14 to 0.15.
D
Sell
3/11/2016Downgrade
Alnylam Pharmaceuticals, Inc. (ALNY) was downgraded to D from D+ on 3/11/2016 due to a significant decline in the volatility index, total return index and efficiency index. Net income declined 18.14% from -$76.79M to -$90.72M, and total capital declined 4.3% from $1.32B to $1.26B.
Alnylam Pharmaceuticals, Inc. (ALNY) was downgraded to D from D+ on 3/11/2016 due to a significant decline in the volatility index, total return index and efficiency index. Net income declined 18.14% from -$76.79M to -$90.72M, and total capital declined 4.3% from $1.32B to $1.26B.
D
Sell
1/28/2016Upgraded
Alnylam Pharmaceuticals, Inc. (ALNY) was upgraded to D+ from D on 1/28/2016 due to an increase in the valuation index.
Alnylam Pharmaceuticals, Inc. (ALNY) was upgraded to D+ from D on 1/28/2016 due to an increase in the valuation index.
D
Sell
1/6/2016Downgrade
Alnylam Pharmaceuticals, Inc. (ALNY) was downgraded to D from D+ on 1/6/2016 due to a substantial decline in the total return index, volatility index and solvency index.
Alnylam Pharmaceuticals, Inc. (ALNY) was downgraded to D from D+ on 1/6/2016 due to a substantial decline in the total return index, volatility index and solvency index.
D
Sell
8/12/2015Downgrade
Alnylam Pharmaceuticals, Inc. (ALNY) was downgraded to D+ from C- on 8/12/2015 due to a noticeable decline in the volatility index, total return index and valuation index.
Alnylam Pharmaceuticals, Inc. (ALNY) was downgraded to D+ from C- on 8/12/2015 due to a noticeable decline in the volatility index, total return index and valuation index.
C
Hold
5/11/2015Upgraded
Alnylam Pharmaceuticals, Inc. (ALNY) was upgraded to C- from D on 5/11/2015 due to a noticeable increase in the total return index, efficiency index and growth index. Net income increased 137.4% from -$21.39M to -$50.78M, earnings per share increased from -$0.2779 to -$0.6187, and total capital increased 59.84% from $936.27M to $1.5B.
Alnylam Pharmaceuticals, Inc. (ALNY) was upgraded to C- from D on 5/11/2015 due to a noticeable increase in the total return index, efficiency index and growth index. Net income increased 137.4% from -$21.39M to -$50.78M, earnings per share increased from -$0.2779 to -$0.6187, and total capital increased 59.84% from $936.27M to $1.5B.
D
Sell
11/10/2014Downgrade
Alnylam Pharmaceuticals, Inc. (ALNY) was downgraded to D from D+ on 11/10/2014 due to a decline in the efficiency index, solvency index and valuation index. The quick ratio declined from 12.18 to 11.12, total capital declined 4.01% from $942.27M to $904.48M, and net income declined 0.19% from -$44.07M to -$43.99M.
Alnylam Pharmaceuticals, Inc. (ALNY) was downgraded to D from D+ on 11/10/2014 due to a decline in the efficiency index, solvency index and valuation index. The quick ratio declined from 12.18 to 11.12, total capital declined 4.01% from $942.27M to $904.48M, and net income declined 0.19% from -$44.07M to -$43.99M.
D
Sell
9/10/2014Upgraded
Alnylam Pharmaceuticals, Inc. (ALNY) was upgraded to D+ from D on 9/10/2014 due to an increase in the total return index and volatility index.
Alnylam Pharmaceuticals, Inc. (ALNY) was upgraded to D+ from D on 9/10/2014 due to an increase in the total return index and volatility index.
D
Sell
8/15/2014Downgrade
Alnylam Pharmaceuticals, Inc. (ALNY) was downgraded to D from D+ on 8/15/2014 due to a large decline in the volatility index, efficiency index and valuation index. Net income declined 82.44% from -$250.94M to -$44.07M, and total capital declined 1.33% from $954.97M to $942.27M.
Alnylam Pharmaceuticals, Inc. (ALNY) was downgraded to D from D+ on 8/15/2014 due to a large decline in the volatility index, efficiency index and valuation index. Net income declined 82.44% from -$250.94M to -$44.07M, and total capital declined 1.33% from $954.97M to $942.27M.
D
Sell
7/16/2014Upgraded
Alnylam Pharmaceuticals, Inc. (ALNY) was upgraded to D+ from D on 7/16/2014 due to an increase in the valuation index and volatility index.
Alnylam Pharmaceuticals, Inc. (ALNY) was upgraded to D+ from D on 7/16/2014 due to an increase in the valuation index and volatility index.
D
Sell
6/9/2014Downgrade
Alnylam Pharmaceuticals, Inc. (ALNY) was downgraded to D from D+ on 6/9/2014 due to a decline in the valuation index.
Alnylam Pharmaceuticals, Inc. (ALNY) was downgraded to D from D+ on 6/9/2014 due to a decline in the valuation index.
D
Sell
5/12/2014Upgraded
Alnylam Pharmaceuticals, Inc. (ALNY) was upgraded to D+ from D on 5/12/2014 due to a major increase in the volatility index, valuation index and efficiency index. Net income increased 675.54% from -$32.36M to -$250.94M, and total capital increased 253.24% from $270.35M to $954.97M.
Alnylam Pharmaceuticals, Inc. (ALNY) was upgraded to D+ from D on 5/12/2014 due to a major increase in the volatility index, valuation index and efficiency index. Net income increased 675.54% from -$32.36M to -$250.94M, and total capital increased 253.24% from $270.35M to $954.97M.
NASDAQ
03/06/2025 4:00PM Eastern
Quotes delayed
